UCSF

Publications

  1. Douglas MP, Kumar A. Analyzing Precision Medicine Utilization with Real-World Data: A Scoping Review. J Pers Med. 2022 Apr 1;12(4):557.
  2. Jansen JP, Trikalinos TA, Phillips KA. Assessments of the Value of New Interventions Should Include Health Equity Impact. Pharmacoeconomics. 2022 Mar 3:1–7. Epub ahead of print.
  3. Deverka PA, Douglas MP, Phillips KA. Multicancer Screening Tests: Anticipating And Addressing Considerations For Payer Coverage And Patient Access. Health Affairs. 2022;41(3): 383-389.
  4. Jansen JP, Linthicum M, Chapman RH. Value Assessment And Decision Making In The Face Of Uncertainty. Health Affairs Forefront. January 26, 2022. https://www.healthaffairs.org/do/10.1377/forefront.20220124.894580
  5. Phillips KA, Redberg RF. Medicare “Coverage with Evidence Development” Leaps into the Spotlight with CMS Draft National Coverage Decision on Alzheimer’s Drugs. Health Affairs Forefront. January 25, 2022. https://www.healthaffairs.org/do/10.1377/forefront.20220124.479741
  6. Douglas MP, Lin GA, Trosman JR, Phillips KA. Hereditary cancer panel testing challenges and solutions for the latinx community: costs, access, and variants. J Community Genet. 2022;13(1):75-80. 
  7. Phillips KA, Trosman JR, Douglas MP, Gelb BD, Ferket BS, Hindorff LA, Slavotinek AM, Berg JS, Russell HV, Devine B, Greve V, Smith HS. US private payers' perspectives on insurance coverage for genome sequencing versus exome sequencing: A study by the Clinical Sequencing Evidence-Generating Research Consortium (CSER). Genet Med. 2022;24(1):238-244.
  8. Arias JJ, Phillips KA, Karlawish J. Developing an Economic and Policy Research Agenda for Blood Biomarkers of Neurodegenerative Diseases. JAMA Health Forum. 2021;2(7):e211428.
  9. Lin GA, Trosman JR, Douglas MP, Weldon CB, Scheuner MT, Kurian AW, Phillips KA. Influence of payer coverage and out-of-pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings. J Genetic Counseling. 2022: 31(1):130-139.
  10. Scheuner MT, Douglas MP, Sales P, Ackerman SL, Phillips KA. Laboratory business models and practices: Implications for availability and access to germline genetic testing. Genet. Med. 2021;23:1681–1688.
  11. Phillips KA, Douglas MP, Wordsworth S, Buchanan J, Marshall DA. Availability and funding of clinical genomic sequencing globally. BMJ Global Health. 2021;6:e004415.
  12. Arias JJ, Tyler AM, Douglas MP, Phillips KA. Private Payer Coverage Policies for ApoE4 Genetic Testing. Genet Med.2021;23:614-620.
  13. Phillips KA, Douglas MP, Marshall DA. Use of Clinical Genomic Sequencing Expands but More Data on Implementation Are Needed. JAMA. 2020;324(20):2029-2030.
  14. Douglas MP, Gray SW, Phillips KA. Private Payer and Medicare Coverage Policies for Circulating Tumor DNA Testing in Cancer Patients: Trends from 2015-2019. J Natl Compr Canc Netw. 2020;18(7):866-872.
  15. Phillips KA. Introduction to Themed Papers: Methods for Moving Evaluation of Precision Medicine into Practice and Policy. Value Health. 2020;23(5):527-528.
  16. Marshall DA, Grazziotin L, Regier DA, Wordsworth S, Buchanan J, Phillips KA, Ijzerman M. Using Simulation and Constraint Optimization Modeling to Address Challenges in Economic Evaluation of Precision Medicine. Value Health. 2020;23(5):566-573.
  17. Mackay Z, Dukhovny D, Parad RB, Phillips KA, Beggs AH, Green RB, Christensen KD. Methods for Identifying Health Care Attributable to Unexpected Genomic Results. Value Health. 2020;23(5):559-565.
  18. Trosman JR, Douglas MP, Liang S, Weldon CB, Kurian AW, Kelley RK, Phillips KA. Insights from a Temporal Assessment of Increases in U.S. Private Payer Coverage of Tumor Sequencing from 2015 to 2019. Value Health. 2020;23(5):551-558.
  19. Deverka PA, Douglas MP, Phillips KA. Use of Real World Evidence in U.S. Payer Coverage Decision-making for NGS-based Tests: Challenges, Opportunities, and Potential Solutions. Value Health. 2020;23(5):540-550.
  20. Phillips KA, Deverka PA. “Policy Implications of Commercial Payer Use of Third Party Benefit Managers: The Example of the Emerging Role of Lab Benefit Managers for Genetic Testing” Health Affairs Blog. https://www.healthaffairs.org/do/10.1377/hblog20191021.563154/full/
  21. Trosman JR, Weldon CB, Slavotinek A, Norton ME, Douglas MP, Phillips KA. Perspectives of US private payers on insurance coverage for pediatric and prenatal exome sequencing: Results of a study from the Program in Prenatal and Pediatric Genomic Sequencing (P3EGS). Genet Med.2020;22(2): 283-291. https://www.ncbi.nlm.nih.gov/pubmed/31501586
  22. Phillips KA, Marshall DA, Kurian AW. Can precision medicine help achieve the goal of reducing care when the risks exceed the benefits? Per Med. 2019 Sep 25. (online ahead of print) https://www.ncbi.nlm.nih.gov/pubmed/31552799
  23. Phillips KA, Trosman JR, Douglas MP. Emergence of Hybrid Models of Genetic Testing Beyond Direct-to-Consumer or Traditional Labs. JAMA. 2019;321(24):2403-2404. https://www.ncbi.nlm.nih.gov/pubmed/31145414
  24. Phillips KA. Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA. 2018;319(23):2379-2380. https://www.ncbi.nlm.nih.gov/pubmed/29710095
  25. Phillips KA, Trosman JR, Deverka PA, Quinn B, Tunis S, Neumann PJ, Chambers JD, Garrison LP, Douglas MP, Weldon CB. Insurance Coverage for Genomic Tests. Science. 2018;360(6386):278-279. https://www.ncbi.nlm.nih.gov/pubmed/29674586
  26. Douglas MP, Parker SL, Trosman JR, Slavotinek AM, Phillips KA. Private Payer Coverage Policies for Exome Sequencing (ES) in Pediatric Patients: Trends Over Time and Analysis of Evidence Cited. Genet Med. 2019;21(1):152-160. https://www.ncbi.nlm.nih.gov/pubmed/29997388
  27. Phillips KA, Douglas MP. The Global Market for Next-Generation Sequencing Tests Continues Its Torrid Pace. Journal Precision Medicine. 2018; https://www.thejournalofprecisionmedicine.com/wp-content/uploads/2018/11/Phillips-Online.pdf
  28. Phillips KA, Trosman JR, Weldon CB, Douglas MP. The New Medicare Coverage Policy for Next Generation Tumor Sequencing: A Key Shift in Coverage Criteria with Broad Implications beyond Medicare. JCO Precis Oncol. 2018 :2, 1-5. https://ascopubs.org/doi/abs/10.1200/PO.18.00206
  29. Phillips KA. Assessing the Value of Next-Generation Sequencing Technologies: An Introduction. Value Health. 2018; 21(9):1031-1032. https://www.ncbi.nlm.nih.gov/pubmed/30224105
  30. Phillips KA, Deverka PA, Marshall DA, Wordsworth S, Regier DA, Christensen KD, Buchanan J. Methodological Challenges and Solutions for Assessing Economic Value of Next Generation Sequencing Tests. Value Health. 2018; 21(9):1033-1042. https://www.ncbi.nlm.nih.gov/pubmed/30224106
  31. Wordsworth S, Doble B, Payne K, Buchanan J, Marshall DA, McCabe C, Regier DA. Using ‘big’ data in the cost-effectiveness analysis of genomic-based diagnostic tests: challenges and potential solutions. Value Health. 2018; 21(9):1048-1053. https://www.ncbi.nlm.nih.gov/pubmed/30224108
  32. Reiger DA, Weymann D, Buchanan J, Marshall DA, Wordsworth S. Valuation of health and non-health Outcomes from Next-Generation Sequencing: Approaches, Challenges, and Solutions. Value Health 2018; 21(9):1043-1047. https://www.ncbi.nlm.nih.gov/pubmed/30224107
  33. Christensen KD, Phillips KA, Green RC, Dukhovny D. Cost Analyses of Genomic Sequencing – Lessons Learned from the MedSeq Project. Value Health. Value Health. 2018; 21(9):1054-1061. https://www.ncbi.nlm.nih.gov/pubmed/30224109
  34. Trosman JR, Weldon CB, Gradishar WJ, Benson AB III, Cristofanilli M, Kurian AW, Ford JM, Balch A, Watkins J, Phillips KA. From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. Value Health. 2018; 21(9):1062-1068. https://www.ncbi.nlm.nih.gov/pubmed/30224110
  35. Christensen KD, Vassy JL, Phillips KA, Blout CL, Azzariti DR, Lu CY, Robinson JO, Lee K, Douglas MP, Yeh JM, Machini K, Stout NK, Rehm HL, McGuire AL, Green RC, Dukhovny D. Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial. Genet Med. 2018; March 22. https://www.ncbi.nlm.nih.gov/pubmed/29565423
  36. Phillips KA, Deverka PA, Douglas MP, Hooker G. Genetic Test Availability and Spending. Where Are We Now? Where Are We Going? Health Affairs. 2018;37(5):710-716. https://www.ncbi.nlm.nih.gov/pubmed/29733704
  37. Ginsburg GS, Phillips KA. Precision Medicine: From Science to Value. Health Affairs. 2018;37(5):694-701. https://www.ncbi.nlm.nih.gov/pubmed/29733705
  38. Phillips KA. Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA. 2018; Apr 16. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/29710095
  39. Phillips KA, Trosman JR, Deverka PA, Quinn B, Tunis S, Neumann PJ, Chambers JD, Garrison LP, Douglas MP, Weldon CB. Insurance Coverage for Genomic Tests. Science. 2018;360(6386):278-279. https://www.ncbi.nlm.nih.gov/pubmed/29674586
  40. Chambers J, Saret C, Anderson J, Deverka, PA, Douglas, MP, Phillips KA. Examining payer coverage policies for multi-gene panels and sequencing tests. IJTAHC. 2017;33(4):534-540. https://www.ncbi.nlm.nih.gov/pubmed/29065945
  41. Phillips KA, Deverka PA, Trosman JR, Douglas MP, Chambers JD, Weldon CB, Dervan AP. Payer Coverage Policies for Multigene Tests. Nature Biotechnol. 2017; 35(7):614-617. https://www.ncbi.nlm.nih.gov/pubmed/28700544
  42. Phillips KA, Deverka PA, Sox HC, Khoury MJ, Sandy LG, Ginsburg GS, Tunis SR, Orlando LA, Douglas MP. Making Genomic Medicine Evidence-Based and Patient-Centered: A Structured Review and Landscape Analysis of Comparative Effectiveness Research. Genet Med. 2017; 19(10):1081-1091. https://www.ncbi.nlm.nih.gov/pubmed/28406488
  43. Trosman JR, Weldon CB, Douglas MP, Kurian AW, Kelley RK, Deverka PA, Phillips KA. Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. J Natl Compr Canc Netw. 2017; Feb;15(2):219-228. https://www.ncbi.nlm.nih.gov/pubmed/28188191
  44. Dervan AP, Deverka PA, Trosman JR, Weldon CB, Douglas MP, and Phillips KA. Payer Decision-Making for Next Generation Sequencing-Based Genetic Tests: Insights from Cell-Free DNA Prenatal Screening. Genet Med. 2017; May;19(5):559-567. https://www.ncbi.nlm.nih.gov/pubmed/27657682
  45. Marshall DA, Gonzalez JM, MacDonald KV, et al. Estimating Preferences for Complex Health Technologies: Lessons Learned and Implications for Personalized Medicine. Value Health. 2017;20(1): 32-39. https://www.ncbi.nlm.nih.gov/pubmed/28212966
  46. Phillips KA, Douglas MP, Trosman JR, et al. "What Goes Around Comes Around": Lessons Learned from Economic Evaluations of Personalized Medicine Applied to Digital Medicine. Value Health. 2017;20(1): 47-53. https://www.ncbi.nlm.nih.gov/pubmed/28212968
  47. Trosman JR, Weldon CB, Douglas MP, et al. Decision-Making on Medical Innovations in a Changing Health Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies. Value Health. 2017;20(1): 40-46. https://www.ncbi.nlm.nih.gov/pubmed/28212967
  48. Marshall DA, MacDonald KV, Oliver Robinson J, Barcellos LF, Gianfrancesco M, Helm M, McGuire A, Green RC, Douglas MP, Goldman MA, Phillips KA. The price of whole genome sequencing may be decreasing, but who will be sequenced? Personalized Medicine. 2017; 14(2): 203-211.
  49. Phillips KA, Deverka PA, Sox HC, Khoury MJ, Sandy LG, Ginsburg GS, Tunis SR, Orlando LA, Douglas MP. Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research. Genet Med. 2017; 19:1081-1091. https://www.ncbi.nlm.nih.gov/pubmed/28406488
  50. Phillips KA, Deverka PA, Trosman JR, Douglas MP, Chambers JD, Weldon CB, Dervan AP. Payer coverage policies for multigene tests. Nat Biotechnol. 2017 Jul 12;35(7):614-617. https://www.ncbi.nlm.nih.gov/pubmed/28700544
  51. Marshall DA, Gonzalez JM, Johnson FR, MacDonald KV, Pugh A, Douglas MP, Phillips KA. What are people willing to pay for whole-genome sequencing information, and who decides what they receive? Genet Med. 2016, 18(2):1295-1302. http://www.ncbi.nlm.nih.gov/pubmed/27253734
  52. Phillips KA, Schleifer D, Hagelskamp C. Most Americans Do Not Believe That There Is An Association Between Health Care Prices And Quality Of Care. Health Affairs. 2016, 35:647-653. http://www.ncbi.nlm.nih.gov/pubmed/27044965
  53. Payne K, Redekop K, and Phillips KA. (2016) Personalized Medicine: Economic Evaluation and Evidence (book chapter). In World Scientific Handbook of Global Health Economics and Public Policy, Vol. 2, edited by Richard M. Scheffler. World Scientific, Imperial College Press. Hackensack, NJ.
  54. Phillips KA, Pletcher MJ, Ladabaum U. Is the “$1000 Genome” Really $1000? Understanding the Full Benefits and Costs of Genomic Sequencing. Technol Health Care 2015. 23(3)373-379. http://www.ncbi.nlm.nih.gov/pubmed/25669213
  55. Trosman JR, Weldon CB, Kelley RK, Phillips KA. Challenges of coverage policy development for next-generation tumor sequencing panels: Experts and Payers Weigh in. JNCCN. 2015. 13(3):311-8. http://www.ncbi.nlm.nih.gov/pubmed/25736008
  56. Phillips KA, Ladabaum U, Pletcher MJ, Marshall DA, Douglas MP. Key emerging themes for assessing the cost-effectiveness of reporting incidental findings. Genet Med. 2015. 17(4):314-5. http://www.ncbi.nlm.nih.gov/pubmed/25835195
  57. Douglas MP, Ladabaum U, Pletcher MJ, Marshall DA, Phillips KA. Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review. Genet Med. 2016. 18(2):111-116. http://www.ncbi.nlm.nih.gov/pubmed/25996638
  58. Clain E, Trosman JR, Douglas MP, Weldon CB, and Phillips KA. Availability and payer coverage of BRCA1/2 tests and gene panels. Nat Biotechnol. 2015. 33(9):900-2. http://www.ncbi.nlm.nih.gov/pubmed/26348951
  59. Garfield, S., M. P. Douglas, K. V. MacDonald, D. A. Marshall and K. A. Phillips (2015). "Consumer familiarity, perspectives and expected value of personalized medicine with a focus on applications in oncology." Personalized Medicine. 12(1): 13-22.
  60. Schink, J. C., J. R. Trosman, C. B. Weldon, K. P. Siziopikou, G. J. Tsongalis, A. W. Rademaker, J. D. Patel, A. B. Benson, 3rd, E. A. Perez and W. J. Gradishar (2014). "Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers." J Natl Cancer Inst 106(10). PMCID: 4176043. http://www.ncbi.nlm.nih.gov/pubmed/25217578
  61. Phillips, K. A., J. R. Trosman, R. K. Kelley, M. J. Pletcher, M. P. Douglas and C. B. Weldon (2014). "Genomic sequencing: assessing the health care system, policy, and big-data implications." Health Aff (Millwood) 33(7): 1246-1253. PMCID: 4113721. http://www.ncbi.nlm.nih.gov/pubmed/25006153
  62. Phillips, K. A., J. Ann Sakowski, J. Trosman, M. P. Douglas, S. Y. Liang and P. Neumann (2014). "The economic value of personalized medicine tests: what we know and what we need to know." Genet Med 16(3): 251-257. PMCID: 3949119. http://www.ncbi.nlm.nih.gov/pubmed/24232413
  63. Phillips, K. A. and Labno, A. (2014). "“SHINING A LIGHT” on Companies Providing Healthcare Price Transparency Data."
  64. Trosman, J. R., C. B. Weldon, J. C. Schink, W. J. Gradishar and A. B. Benson, 3rd (2013). "What do providers, payers and patients need from comparative effectiveness research on diagnostics? The case of HER2/Neu testing in breast cancer." J Comp Eff Res 2(4): 461-477. http://www.ncbi.nlm.nih.gov/pubmed/24236686
  65. Shin, J., S. Y. Liang, M. J. Hassett, K. A. Phillips and J. S. Haas (2013). "Utilization of cardiac monitoring tests in women with non-metastatic breast cancer treated with trastuzumab." Personalized Medicine 10(7): 703-708.
  66. Phillips, K. A., J. S. Sakowski, S. Y. Liang and N. A. Ponce (2013). "Economic Perspectives on Personalized Health Care and Prevention. ." Forum for Health Economics and Policy. 16(2): S23-S52. http://www.degruyter.com/view/j/fhep.2013.16.issue-2/fhep-2013-0010/fhep-2013-0010.xml?rskey=dVaq6A&result=4
  67. Kuppermann, M., G. Wang, S. Wong, A. Blanco, P. Conrad, S. Nakagawa, J. Terdiman and U. Ladabaum (2013). "Preferences for outcomes associated with decisions to undergo or forgo genetic testing for Lynch syndrome." Cancer 119(1): 215-225. http://www.ncbi.nlm.nih.gov/pubmed/22786716
  68. Ferrusi, I. L., C. C. Earle, M. Trudeau, N. B. Leighl, E. Pullenayegum, H. Khong, J. S. Hoch and D. A. Marshall (2013). "Closing the personalized medicine information gap: HER2 test documentation practice." Am J Manag Care 19(1): 838-844. PMCID: 3919466. http://www.ncbi.nlm.nih.gov/pubmed/23379747
  69. Weldon, C. B., J. R. Trosman, W. J. Gradishar, A. B. Benson, 3rd and J. C. Schink (2012). "Barriers to the use of personalized medicine in breast cancer." J Oncol Pract 8(4): e24-31. PMCID: 3396824. http://www.ncbi.nlm.nih.gov/pubmed/23180995
  70. Wang, G., M. Kuppermann, B. Kim, K. A. Phillips and U. Ladabaum (2012). "Influence of patient preferences on the cost-effectiveness of screening for Lynch syndrome." Am J Manag Care 18(5): e179-185. http://www.ncbi.nlm.nih.gov/pubmed/22694112
  71. Wang, G., M. Kuppermann, B. Kim, K. A. Phillips and U. Ladabaum (2012). "Influence of patient preferences on the cost-effectiveness of screening for lynch syndrome." J Oncol Pract 8(3 Suppl): e24s-30s. PMCID: 3348599. http://www.ncbi.nlm.nih.gov/pubmed/22942831
  72. Walsh, J., M. Arora, C. Hosenfeld, U. Ladabaum, M. Kuppermann and S. J. Knight (2012). "Preferences for genetic testing to identify hereditary colorectal cancer: perspectives of high-risk patients, community members, and clinicians." J Cancer Educ 27(1): 112-119. http://www.ncbi.nlm.nih.gov/pubmed/22131063
  73. Ponce, N. A., J. Tsui, S. J. Knight, A. Afable-Munsuz, U. Ladabaum, R. A. Hiatt and J. S. Haas (2012). "Disparities in cancer screening in individuals with a family history of breast or colorectal cancer." Cancer 118(6): 1656-1663. PMCID: 3262934. http://www.ncbi.nlm.nih.gov/pubmed/22009719
  74. Ladabaum, U. and J. M. Ford (2012). "Lynch syndrome in patients with colorectal cancer: finding the needle in the haystack." JAMA 308(15): 1581-1583. http://www.ncbi.nlm.nih.gov/pubmed/23073955
  75. Kelley, R. K., C. Atreya, A. P. Venook and P. G. Febbo (2012). "Predictive biomarkers in advance of a companion drug: ahead of their time?" J Natl Compr Canc Netw 10(3): 303-309. http://www.ncbi.nlm.nih.gov/pubmed/22393192
  76. Beattie, M. S., G. Wang and K. A. Phillips (2012). "Differences in US healthcare coverage policies in BRCA testing and potential implications." Personalized Medicine. 9(1): 5-8.
  77. Wang, G., M. S. Beattie, N. A. Ponce and K. A. Phillips (2011). "Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling." Genet Med 13(12): 1045-1050. http://www.ncbi.nlm.nih.gov/pubmed/21844812
  78. Trosman, J. R., S. L. Van Bebber and K. A. Phillips (2011). "Health technology assessment and private payers's coverage of personalized medicine." Am J Manag Care 17 Suppl 5 Developing: SP53-60. http://www.ncbi.nlm.nih.gov/pubmed/21711078
  79. Trosman, J. R., S. L. Van Bebber and K. A. Phillips (2011). "Health technology assessment and private payers' coverage of personalized medicine." J Oncol Pract 7(3 Suppl): 18s-24s. PMCID: 3092460. http://www.ncbi.nlm.nih.gov/pubmed/21886515
  80. Pletcher, M. J. and M. Pignone (2011). "Evaluating the clinical utility of a biomarker: a review of methods for estimating health impact." Circulation 123(10): 1116-1124. PMCID: 3138723. http://www.ncbi.nlm.nih.gov/pubmed/21403122
  81. Odierna, D. H., A. Afable-Munsuz, O. Ikediobi, M. Beattie, S. Knight, M. Ko, A. Wilson and N. A. Ponce (2011). "Early developments in gene-expression profiling of breast tumors: potential for increasing black-white patient disparities in breast cancer outcomes?" Per Med 8(6): 669-679. PMCID: 3242007. http://www.ncbi.nlm.nih.gov/pubmed/22190978
  82. Lorizio, W., H. Rugo, M. S. Beattie, S. Tchu, T. Melese, M. Melisko, A. H. Wu, H. J. Lawrence, M. Nikoloff and E. Ziv (2011). "Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment." Genome Med 3(10): 64. PMCID: 3239226. http://www.ncbi.nlm.nih.gov/pubmed/21970596
  83. Liang, S. Y., K. A. Phillips, G. Wang, C. Keohane, J. Armstrong, W. M. Morris and J. S. Haas (2011). "Tradeoffs of using administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer." Med Care 49(6): e1-8. PMCID: 3383782. http://www.ncbi.nlm.nih.gov/pubmed/21422962
  84. Ladabaum, U., G. Wang, J. Terdiman, A. Blanco, M. Kuppermann, C. R. Boland, J. Ford, E. Elkin and K. A. Phillips (2011). "Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis." Ann Intern Med 155(2): 69-79. PMCID: 3793257. http://www.ncbi.nlm.nih.gov/pubmed/21768580
  85. Kelley, R. K., G. Wang and A. P. Venook (2011). "Biomarker use in colorectal cancer therapy." J Natl Compr Canc Netw 9(11): 1293-1302. PMCID: 3696980. http://www.ncbi.nlm.nih.gov/pubmed/22056657
  86. Kelley, R. K. and A. P. Venook (2011). "Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?" Clin Colorectal Cancer 10(2): 73-80. PMCID: 3561586. http://www.ncbi.nlm.nih.gov/pubmed/21859557
  87. Kelley, R. K., S. L. Van Bebber, K. A. Phillips and A. P. Venook (2011). "Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer." J Natl Compr Canc Netw 9(1): 13-25. PMCID: 3695822. http://www.ncbi.nlm.nih.gov/pubmed/21233242
  88. Johnson, F. R., A. F. Mohamed, S. Ozdemir, D. A. Marshall and K. A. Phillips (2011). "How does cost matter in health-care discrete-choice experiments?" Health Econ 20(3): 323-330. PMCID: 3918954. http://www.ncbi.nlm.nih.gov/pubmed/20217834
  89. Haas, J. S., K. A. Phillips, S. Y. Liang, M. J. Hassett, C. Keohane, E. B. Elkin, J. Armstrong and M. Toscano (2011). "Genomic testing and therapies for breast cancer in clinical practice." Am J Manag Care 17(5 Spec No): e174-181. http://www.ncbi.nlm.nih.gov/pubmed/21711068
  90. Haas, J. S., K. A. Phillips, S. Y. Liang, M. J. Hassett, C. Keohane, E. B. Elkin, J. Armstrong and M. Toscano (2011). "Genomic testing and therapies for breast cancer in clinical practice." J Oncol Pract 7(3 Suppl): e1s-7s. PMCID: 3092459. http://www.ncbi.nlm.nih.gov/pubmed/21886507
  91. Haas, J. S., S. Y. Liang, M. J. Hassett, S. Shiboski, E. B. Elkin and K. A. Phillips (2011). "Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care." Breast Cancer Res Treat 130(2): 619-626. PMCID: 3590013. http://www.ncbi.nlm.nih.gov/pubmed/21681446
  92. Ferrusi, I. L., N. B. Leighl, N. A. Kulin and D. A. Marshall (2011). "Do economic evaluations of targeted therapy provide support for decision makers?" Am J Manag Care 17 Suppl 5 Developing: SP61-70. PMCID: 3918963. http://www.ncbi.nlm.nih.gov/pubmed/21711079
  93. Ferrusi, I. L., N. B. Leighl, N. A. Kulin and D. A. Marshall (2011). "Do economic evaluations of targeted therapy provide support for decision makers?" J Oncol Pract 7(3 Suppl): 36s-45s. PMCID: 3092467. http://www.ncbi.nlm.nih.gov/pubmed/21886518
  94. Ferrusi, I. L., N. B. Leighl, N. A. Kulin and D. A. Marshall (2011). "Do economic evaluations of targeted therapy provide support for decision makers?" J Oncol Pract 7(3 Suppl): 36s-45s. PMCID: 3092467. http://www.ncbi.nlm.nih.gov/pubmed/21886518
  95. Elkin, E. B., D. A. Marshall, N. A. Kulin, I. L. Ferrusi, M. J. Hassett, U. Ladabaum and K. A. Phillips (2011). "Economic evaluation of targeted cancer interventions: critical review and recommendations." Genet Med 13(10): 853-860. PMCID: 3774033. http://www.ncbi.nlm.nih.gov/pubmed/21637102
  96. Arar, N., S. J. Knight, S. M. Modell and A. M. Issa (2011). "The Genome-based Knowledge Management in Cycles model: a complex adaptive systems framework for implementation of genomic applications." Personalized Medicine. 8(2): 191-205.
  97. Wang, G., R. K. Kelley and Gappnet (2010). "KRAS mutational analysis for colorectal cancer. Application: pharmacogenomic." PLoS Curr 2. PMCID: 2940138. http://www.ncbi.nlm.nih.gov/pubmed/20877448
  98. Van Bebber, S. L., J. R. Trosman, S. Y. Liang, G. Wang, D. A. Marshall, S. Knight and K. A. Phillips (2010). "Capacity building for assessing new technologies: approaches to examining personalized medicine in practice." Per Med 7(4): 427-439. PMCID: 3157083. http://www.ncbi.nlm.nih.gov/pubmed/21857867
  99. Trosman, J. R., S. L. Van Bebber and K. A. Phillips (2010). "Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay." J Oncol Pract 6(5): 238-242. PMCID: 2936466. http://www.ncbi.nlm.nih.gov/pubmed/21197187
  100. Marshall, D., S. E. McGregor and G. Currie (2010). "Measuring Preferences for Colorectal Cancer Screening: What are the Implications for Moving Forward?" Patient 3(2): 79-89. http://www.ncbi.nlm.nih.gov/pubmed/22273359
  101. Ladabaum, U., A. Ferrandez and A. Lanas (2010). "Cost-effectiveness of colorectal cancer screening in high-risk Spanish patients: use of a validated model to inform public policy." Cancer Epidemiol Biomarkers Prev 19(11): 2765-2776. PMCID: 3159034. http://www.ncbi.nlm.nih.gov/pubmed/20810603
  102. Kelley, R. K. and A. P. Venook (2010). "Nonadherence to imatinib during an economic downturn." N Engl J Med 363(6): 596-598. http://www.ncbi.nlm.nih.gov/pubmed/20818898
  103. Kelley, R. K. (2010). "What clinicians need to know about molecular markers in solid tumors. MedscapeCME Oncology. ." Retrieved 1/12/2015, 2015, from http://www.medscape.org/viewarticle/725989.
  104. Johnson, F. R., S. Ozdemir and K. A. Phillips (2010). "Effects of simplifying choice tasks on estimates of taste heterogeneity in stated-choice surveys." Soc Sci Med 70(2): 183-190. PMCID: 3152257. http://www.ncbi.nlm.nih.gov/pubmed/19880234
  105. Elkin, E. B. and P. B. Bach (2010). "Cancer's next frontier: addressing high and increasing costs." JAMA 303(11): 1086-1087. PMCID: 3647336. http://www.ncbi.nlm.nih.gov/pubmed/20233828
  106. Cheung, E. L., A. D. Olson, T. M. Yu, P. Z. Han and M. S. Beattie (2010). "Communication of BRCA results and family testing in 1,103 high-risk women." Cancer Epidemiol Biomarkers Prev 19(9): 2211-2219. PMCID: 3207738. http://www.ncbi.nlm.nih.gov/pubmed/20699375
  107. Bowen, D. J., J. Harris, C. M. Jorgensen, M. F. Myers and A. Kuniyuki (2010). "Socioeconomic influences on the effects of a genetic testing direct-to-consumer marketing campaign." Public Health Genomics 13(3): 131-142. http://www.ncbi.nlm.nih.gov/pubmed/19641293
  108. Wideroff, L., K. A. Phillips, G. Randhawa, A. Ambs, K. Armstrong, C. L. Bennett, M. L. Brown, M. S. Donaldson, M. Follen, S. J. Goldie, R. A. Hiatt, M. J. Khoury, G. Lewis, H. L. McLeod, M. Piper, I. Powell, D. Schrag, K. A. Schulman and J. Scott (2009). "A health services research agenda for cellular, molecular and genomic technologies in cancer care." Public Health Genomics 12(4): 233-244. PMCID: 2844634. http://www.ncbi.nlm.nih.gov/pubmed/19367091
  109. Shaukat, A., M. Parekh, J. Lipscomb and U. Ladabaum (2009). "Can calcium chemoprevention of adenoma recurrence substitute or serve as an adjunct for colonoscopic surveillance?" Int J Technol Assess Health Care 25(2): 222-231. PMCID: 2972652. http://www.ncbi.nlm.nih.gov/pubmed/19331713
  110. Phillips, K. A., D. A. Marshall, J. S. Haas, E. B. Elkin, S. Y. Liang, M. J. Hassett, I. Ferrusi, J. E. Brock and S. L. Van Bebber (2009). "Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients." Cancer 115(22): 5166-5174. PMCID: 2783254. http://www.ncbi.nlm.nih.gov/pubmed/19753618
  111. Marshall, D. A., F. R. Johnson, N. A. Kulin, S. Ozdemir, J. M. Walsh, J. K. Marshall, S. Van Bebber and K. A. Phillips (2009). "How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated-choice survey." Health Econ 18(12): 1420-1439. PMCID: 3964796. http://www.ncbi.nlm.nih.gov/pubmed/19191268
  112. Marshall, D. A. and M. Hux (2009). "Design and analysis issues for economic analysis alongside clinical trials." Med Care 47(7 Suppl 1): S14-20. http://www.ncbi.nlm.nih.gov/pubmed/19536012
  113. Liang, S. Y., J. S. Haas and K. A. Phillips (2009). "Medicare formulary coverage for top-selling biologics." Nat Biotechnol 27(12): 1082-1084. PMCID: 2845541. http://www.ncbi.nlm.nih.gov/pubmed/20010576
  114. Ikediobi, O. N., J. Shin, R. L. Nussbaum, K. A. Phillips, J. M. Walsh, U. Ladabaum and D. Marshall (2009). "Addressing the challenges of the clinical application of pharmacogenetic testing." Clin Pharmacol Ther 86(1): 28-31. PMCID: 2910521. http://www.ncbi.nlm.nih.gov/pubmed/19536122
  115. Hay, J., J. N. Harris, E. A. Waters, M. F. Clayton, L. Ellington, A. D. Abernethy and H. Prayor-Patterson (2009). "Personal communication in primary and secondary cancer prevention: evolving discussions, emerging challenges." J Health Commun 14 Suppl 1: 18-29. http://www.ncbi.nlm.nih.gov/pubmed/19449265
  116. Harris, J. N., D. J. Bowen, A. Kuniyuki, L. McIntosh, L. M. FitzGerald, E. A. Ostrander and J. L. Stanford (2009). "Interest in genetic testing among affected men from hereditary prostate cancer families and their unaffected male relatives." Genet Med 11(5): 344-355. PMCID: 2683189. http://www.ncbi.nlm.nih.gov/pubmed/19346959
  117. Harris, J., D. J. Bowen, H. Badr, P. Hannon, J. Hay and K. Regan Sterba (2009). "Family communication during the cancer experience." J Health Commun 14 Suppl 1: 76-84. http://www.ncbi.nlm.nih.gov/pubmed/19449271
  118. Ferrusi, I. L., D. A. Marshall, N. A. Kulin, N. B. Leighl and K. A. Phillips (2009). "Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses." Per Med 6(2): 193-215. PMCID: 2910630. http://www.ncbi.nlm.nih.gov/pubmed/20668661
  119. Afable-Munsuz, A., S. Y. Liang, N. A. Ponce and J. M. Walsh (2009). "Acculturation and colorectal cancer screening among older Latino adults: differential associations by national origin." J Gen Intern Med 24(8): 963-970. PMCID: 2710471. http://www.ncbi.nlm.nih.gov/pubmed/19472016
  120. Phillips, K. A., S. Y. Liang and S. Van Bebber (2008). "Challenges to the translation of genomic information into clinical practice and health policy: Utilization, preferences and economic value." Curr Opin Mol Ther 10(3): 260-266. PMCID: 2910510. http://www.ncbi.nlm.nih.gov/pubmed/18535933
  121. Phillips, K. A. (2008). "Closing the evidence gap in the use of emerging testing technologies in clinical practice." JAMA 300(21): 2542-2544. PMCID: 2910511. http://www.ncbi.nlm.nih.gov/pubmed/19050197
  122. Payne, K., W. G. Newman, D. Gurwitz, D. Ibarreta and K. A. Phillips (2008). "TPMT testing in azathioprine: a ‘cost-effective use of healthcare resources’?" Personalized Medicine 6(1): 103-113.
  123. Parekh, M., A. M. Fendrick and U. Ladabaum (2008). "As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia." Aliment Pharmacol Ther 27(8): 697-712. PMCID: 3170173. http://www.ncbi.nlm.nih.gov/pubmed/18248653

Learn more about our work

Subscribe to our newsletter by emailing [email protected].